Clinical Trials Directory

Trials / Completed

CompletedNCT05793957

Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms

Anxiety in the Context of Chemotherapy Infusion: Is There an Association Between the Use of Virtual Reality Goggles and Changes in Anxiety-Related Symptoms?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
OHSU Knight Cancer Institute · Academic / Other
Sex
All
Age
18 Years – 89 Years
Healthy volunteers
Not accepted

Summary

This clinical trial evaluates the use of virtual reality (VR) goggles during chemotherapy infusion to reduce anxiety-related symptoms in patients with head and neck, thoracic, hematologic, and breast cancers. Virtual reality headsets provide the ability for users to explore a simulated, three-dimensional environment with which users can interact. In virtual reality users can play interactive games, enjoy relaxing experiences, and watch immersive videos. The use of VR goggles may help with anxiety management during chemotherapy infusion.

Detailed description

PRIMARY OBJECTIVE: I. To evaluate the effectiveness of VR therapy in reducing severity of anxiety symptoms during chemotherapy infusion, compared to participants utilizing a smartphone as a control. SECONDARY OBJECTIVES: I. To evaluate whether there is a short-term effect of VR use in anxiety levels. II. To assess participant satisfaction with their chemotherapy infusion experience in the control and treatment groups. EXPLORATORY OBJECTIVE: I. To assess participants' reported adverse effects associated with VR headset use. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP 1: Patients use VR during chemotherapy infusion on study. GROUP 2: Patients use smartphone during chemotherapy infusion on study.

Conditions

Interventions

TypeNameDescription
OTHERQuestionnaire AdministrationAncillary studies
BEHAVIORALTelephone-Based InterventionUse smartphone
OTHERVirtual Technology InterventionUse VR headset

Timeline

Start date
2023-04-20
Primary completion
2023-09-28
Completion
2023-09-28
First posted
2023-03-31
Last updated
2023-12-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05793957. Inclusion in this directory is not an endorsement.